Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.
Athanasios D AnastasilakisStergios A PolyzosMaria P YavropoulouCharikleia NtentiStylianos MandanasPolyzois MakrasPublished in: Endocrine (2021)